Heterozygous inhibition in prion infection: The stone fence model

Prion

Volumn 3, Issue 1, 2009, Pages 27-30

  Kobayashi, Atsushi ^a   Hizume, Masaki ^a,c   Teruya, Kenta ^a   Mohri, Shirou ^b   Kitamoto, Tetsuyuki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Conversion; Creutzfeldt Jakob disease; Heterozygous inhibition; Knock in mouse; Polymorphism; Prion protein; Stone fence model

Indexed keywords

GLUTAMIC ACID; LYSINE; METHIONINE; PRION PROTEIN; VALINE;

CODON; CREUTZFELDT JAKOB DISEASE; GENE CONVERSION; GENE REPRESSION; GENETIC MODEL; HETEROZYGOSITY; HOMOZYGOTE; HUMAN; INHIBITION KINETICS; MOLECULAR DYNAMICS; NONHUMAN; PRION; PROTEIN PROCESSING; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; GENE KNOCK-IN TECHNIQUES; HETEROZYGOTE; HUMANS; MICE; MICE, TRANSGENIC; POLYMORPHISM, GENETIC; PRION DISEASES; PRIONS;

ANIMALIA; MUS;

EID: 66749165209     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.3.1.8514     Document Type: Review

References (35)

1. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. Cell 1998; 93: 337-348
2. Doh-ura K, Tateishi J, Sasaki H, Kitamoto T, Sakaki Y. Pro-Leu change at position 102 of prion protein is the most common but not the sole mutation related to Gerstmann-Sträussler syndrome. Biochem Biophys Res Commun 1989; 163:974-979
3. Kitamoto T, Tateishi J. Human prion diseases with variant prion protein. Phil Trans R Soc Lond B Biol Sci 1994; 343:391-398
4. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337:1441-1442
5. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991; 352:340-342
6. Doh-ura K, Kitamoto T, Sakaki Y, Tateishi J. CJD discrepancy. Nature 1991; 353:801-802
7. Zeidler M, Stewart G, Cousens SN, Estibeiro K, Will RG. Codon 129 genotype and new variant CJD. Lancet 1997; 350:668.
8. Alperovitch A, Zerr I, Pocchiari M, Mitrova E, de Pedro Cuesta J, Hegyi I, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353:1673-1674
9. Shibuya S, Higuchi J, Shin R-W, Tateishi J, Kitamoto T. Codon 219 Lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1998; 43:826-828
10. Asano M, Mohri S, Ironside JW, Ito M, Tamaoki N, Kitamoto T. vCJD prion acquires altered virulence through trans-species infection. Biochem Biophys Res Commun 2006; 342:293-299
11. Hizume M, Kobayashi A, Teruya K, Ohashi H, Ironside JW, Mohri S, et al. Human prion protein (PrP) 219K is converted to PrPSc but shows heterozygous inhibition in vCJD infection. J Biol Chem 2009; 284:3603-3609
12. Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, Cohen FE, et al. Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein. Cell 1995; 83:79-90.
13. Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73:1339-1347
14. Horiuchi M, Priola SA, Chabry J, Caughey B. Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci USA 2000; 97:5836-5841
15. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA 1997; 94:10069-10074
16. Perrier V, Kaneko K, Safar J, Vergara J, Tremblay P, DeArmond SJ, et al. Dominant-negative inhibition of prion replication in transgenic mice. Proc Natl Acad Sci USA 2002; 99:13079-13084
17. Kishida H, Sakasegawa Y, Watanabe K, Yamakawa Y, Nishijima M, Kuroiwa Y, et al. Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPSc replication in vitro. Amyloid 2003; 11:14-20.
18. Crozet C, Lin Y-L, Mettling C, Mourton-Gilles C, Corbeau P, Lehmann S, et al. Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations. J Cell Sci 2004; 117:5591-5597
19. Atarashi R, Sim VL, Nishida N, Caughey B, Katamine S. Prion strain-dependent differences in conversion of mutant prion proteins in cell culture. J Virol 2006; 80:7854-7862
20. Furuya K, Kawahara N, Yamakawa Y, Kishida H, Hachiya NS, Nishijima M, et al. Intracerebroventricular delivery of dominant negative prion protein in a mouse model of iatrogenic Creutzfeldt-Jakob disease after dura graft transplantation. Neurosci Lett 2006; 402:222-226
21. Toupet K, Compan V, Crozet C, Mourton-Gilles C, Mestre-Francés N, Ibos F, et al. Effective gene therapy in a mouse model of prion diseases. PLoS One 2008; 23:e2773.
22. Ott D, Taraborrelli C, Aguzzi A. Novel dominant-negative prion protein mutants identified from a randomized library. Protein Eng Des Sel 2008; 21:623-629
23. Meier P, Genoud N, Prinz M, Maissen M, Rülicke T, Zurbriggen A, et al. Soluble dimeric prion protien binds PrPSc in vivo and antagonizes prion disease. Cell 2003; 113:49-60.
24. Lee CI, Yang Q, Perrier V, Baskakov IV. The dominant-negative effect of the Q218K variant of the prion protein does not require protein X. Protein Sci 2007; 16:2166-2173
25. Harper JD, Lansbury Jr PT. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997; 66:385-407.
26. Govaerts C, Wille H, Prusiner SB, Cohen FE. Evidence for assembly of prions with left-handed β-helices into trimers. Proc Natl Acad Sci USA 2004; 101:8342-8347
27. DeMarco ML, Daggett V. From conversion to aggregation: Protofibril formation of the prion protein. Proc Natl Acad Sci USA 2004; 101:2293-2298
28. Langedijk JPM, Fuentes G, Boshuizen R, Bonvin AMJJ. Two-rung model of a left-handed β-helix for prions explains species barrier and strain variation in transmissible spongiform encephalopathies. J Mol Biol 2006; 360:907-920
29. Dickinson AG, Fraser H, Meikle VM, Outram GW. Competition between different scrapie agents in mice. Nat New Biol 1972; 237:244-245
30. Manuelidis L. Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent. Proc Natl Acad Sci 1998; 95:2520-2525
31. Bartz JC, Kramer ML, Sheehan MH, Hutter JAL, Ayers JI, Bessen RA, et al. Prion interference is due to a reduction in strain-specific PrPSc levels. J Virol 2007; 81:689-697
32. Gerber R, Voitchovsky K, Mitchel C, Tahiri-Alaoui A, Ryan JF, Hore PJ, et al. Interoligomer interactions of the human prion protein are modulated by the polymorphism at codon 129. J Mol Biol 2008; 381:212-220
33. Arimon M, Díez-Pérez I, Kogan MJ, Durany N, Giralt E, Sanz F, et al. Fine structure study of Aβ1-42 fibrillogenesis with atomic force microscopy. FASEB J 2005; 19:1344-1346
34. Nishida N, Katamine S, Manuelidis L. Reciprocal interference between specific CJD and scrapie agents in neural cell cultures. Science 2005; 310:493-496
35. Kobayashi A, Asano M, Mohri S, Kitamoto T. Cross-sequence transmission of sporadic Creutzfeldt-Jakob disease creates a new prion strain. J Biol Chem 2007; 282:30022-30028